- Home
- MAIA vs TIL Comparison
MAIA vs TIL Comparison
Compare MAIA & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAIA | TIL |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | United States |
| Employees | 13 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.7M | 74.7M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MAIA | TIL |
|---|---|---|
| Price | $1.53 | $8.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $125.00 |
| AVG Volume (30 Days) | ★ 1.1M | 39.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.53 | ★ 52.54 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.87 | $5.67 |
| 52 Week High | $3.19 | $42.75 |
Technical Indicators
Market Signals| Indicator | MAIA | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 38.48 | 45.02 |
| Support Level | $1.20 | $8.14 |
| Resistance Level | $1.66 | $9.81 |
| Average True Range (ATR) | 0.16 | 0.56 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 13.43 | 17.05 |
Price Performance
Historical ComparisonAbout MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.